Comparative Pharmacology
Head-to-head clinical analysis: RAU SED versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAU SED versus RAUWOLFIA SERPENTINA.
RAU-SED vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive